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for patients with type 2 diabetes
Tracey Jhita1*, Stavros Petrou1, Anil Gumber2, Ala Szczepura1, Neil T Raymond1 and Srikanth Bellary3Abstract
Background: The objective of this study was to investigate the association between ethnicity and health related
quality of life (HRQoL) in patients with type 2 diabetes.
Methods: The EuroQol EQ-5D measure was administered to 1,978 patients with type 2 diabetes in the UK Asian
Diabetes Study (UKADS): 1,486 of south Asian origin (Indian, Pakistani, Bangladeshi or other south Asian) and 492 of
white European origin. Multivariate regression using ordinary least square (OLS), Tobit, fractional logit and Censored
Least Absolutes Deviations estimators was used to estimate the impact of ethnicity on both visual analogue scale
(VAS) and utility scores for the EuroQol EQ-5D.
Results: Mean EQ-5D VAS and utility scores were lower among south Asians with diabetes compared to the white
European population; the unadjusted effect on the mean EQ-5D VAS score was −7.82 (Standard error [SE] = 1.06,
p < 0.01) and on the EQ-5D utility score was −0.06 (SE = 0.02, p < 0.01) (OLS estimator). After controlling for
socio-demographic and clinical confounders, the adjusted effect on the EQ-5D VAS score was −9.35 (SE = 2.46,
p < 0.01) and on the EQ-5D utility score was 0.06 (SE = 0.04), although the latter was not statistically significant.
Conclusions: There was a large and statistically significant association between south Asian ethnicity and lower
EQ-5D VAS scores. In contrast, there was no significant difference in EQ-5D utility scores between the south Asian and
white European sub-groups. Further research is needed to explain the differences in effects on subjective EQ-5D VAS
scores and population-weighted EQ-5D utility scores in this context.
Keywords: Type 2 diabetes, Health related quality of life, EQ-5D, Ethnicity, South AsianBackground
Diabetes is a chronic metabolic disease estimated to have
affected 285 million people globally in 2010, with the
prevalence expected to increase to 438 million people by
2030 [1]. In the UK, there were approximately 2.8 million
people with some form of diabetes in 2010 and, of those,
90% had type 2 diabetes [1]. Type 2 diabetes prevalence is
reported to be three to four times higher in south Asian
adults and the disease may occur a decade earlier than in
the white European majority population in the UK [2,3].
Type 2 diabetes is associated with micro and macro vascu-
lar complications, including increased risk of cardiovascular
disease, diabetic nephropathy, retinopathy, neuropathy and
lower extremity amputations [4]. Type 2 diabetes and its
associated co-morbidities may impact on many areas of an* Correspondence: tracey.jhita.1@city.ac.uk
1Division of Health Sciences, Warwick Medical School, The University of
Warwick, Coventry CV4 7AL, UK
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reproduction in any medium, provided the orindividual’s life, including physical function, social inter-
action and mental well-being; patients may consequently
experience impaired health related quality of life (HRQoL).
There is evidence to suggest that the prevalence, disease
progression and treatment outcomes for people with type
2 diabetes vary significantly between ethnic groups [5-9],
but very little research has been undertaken to date to
directly assess the extent to which ethnicity impacts on
HRQoL in adults with diabetes. In addition, in the few
studies that have explored this relationship, there is incon-
sistency in the tools used to measure HRQoL and a lack
of consensus about the optimum method of assessment.
This, combined with differences in the black and minority
ethnic (BME) populations studied, have resulted in both
negative [5-7,9-11] and positive [12-14] associations being
reported between ethnicity and HRQoL. Although ethni-
city may have an independent effect on HRQoL for people
with type 2 diabetes, the size of any effect is unclear. Mored. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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policy makers and service providers with evidence to
develop initiatives that improve HRQoL for those ethnic
minority populations that are most detrimentally affected.
Furthermore, government agencies in many nations, such
as the National Institute for Health and Care Excellence
(NICE) in England and Wales, rely on cost-utility analyses,
which seek to maximise Quality Adjusted Life Year
(QALY) based measures of benefit that contain a HRQoL
component. If there are ethnic differences in how a dis-
ease such as diabetes affects HRQoL, this should be taken
into account when considering the introduction of new
interventions on cost-effectiveness grounds.
The aim of the study was to investigate the association
between ethnicity and HRQoL in patients with type 2 dia-
betes where HRQoL was measured using visual analogue
scale (VAS) and utility scores for the EuroQol EQ-5D
measure [15].
Methods
This research used data collected by the UK Asian Diabetes
Study (UKADS), which comprised of a community-based,
cluster randomized controlled trial that evaluated the ef-
fectiveness of a culturally sensitive enhanced care package
in UK general practice in improving cardiovascular risk
factors in south Asian patients with type 2 diabetes, plus a
parallel cohort study of cardiovascular risk factors in south
Asian and white European patients with type 2 diabetes
[3]. The main study, carried out in 2004–2007, recruited
a total of 1486 south Asian and 492 white European
patients from 25 general practices in Birmingham (16
practices) and Coventry (9 practices). All adults with type
2 diabetes were eligible for inclusion in the study; people
with type 1 diabetes or impaired glucose tolerance were
excluded. The research reported in this paper uses a
cross-sectional study design, comparing HRQoL data for
south Asian and white European patients in UKADS at
the baseline assessment.
HRQoL was measured using the EuroQol EQ-5D, which
is the generic, multi-attribute, preference based measure
preferred by NICE for cost-effectiveness comparative pur-
poses [16,17]. The EQ-5D consists of two principal mea-
surement components. The first is a descriptive system,
which defines health-related quality of life in terms of five
dimensions: ‘mobility’, ‘self care’, ‘usual activities’, ‘pain/
discomfort’ and ‘anxiety/depression’. Responses in each
dimension are divided into three ordinal levels coded: (1)
no problems; (2) some or moderate problems; and (3) se-
vere or extreme problems. A total of 243 (35) health states
are generated by the EQ-5D descriptive system. For the
purposes of this study, the York A1 (Dolan) tariff was ap-
plied to each set of responses to generate an EQ-5D utility
score (preference weight) for each patient [16]. The York
A1 tariff set was derived from a survey of the UK generalpopulation (n = 3337) which used the time trade-off va-
luation method to estimate utility scores for a subset of 45
EQ-5D health states, with the remainder of the EQ-5D
health states subsequently valued through the estimation
of a multivariate model [17]. Resulting utility scores range
from scores −0.59 to 1.0, with 0 representing death and
1.0 representing full health; values below 0 indicate health
states worse than death. The second measurement com-
ponent of the EQ-5D consists of a 20 cm vertical visual
analogue scale ranging from 100 (best imaginable health
state) to 0 (worst imaginable health state), which provides
an indication of the subject’s own assessment of their
health status on the day of the survey.
Descriptive statistics were produced for baseline cha-
racteristics and analysed by ethnic meta-group (white
European vs. south Asian) and by south Asian subgroup
(Indian, Pakistani, Bangladeshi and other south Asian).
Chi-squared and t-tests were employed to compare base-
line variables between ethnic meta-groups and between
ethnic subgroups. A descriptive analysis of levels of
function within each EQ-5D dimension by ethnicity was
complemented by further analysis of sub-optimal levels
of function (defined as level 2 or 3) for each EQ-5D
dimension. Fisher’s exact test for equality of proportions
was used to compare sub-optimal levels of function within
each EQ-5D dimension between ethnic meta-groups.
Four alternative methods of multivariate analysis were
used to model the association between EQ-5D VAS or
utility scores (dependent variables) and ethnicity: ordinary
least squares (OLS), Tobit, fractional logit (Flogit) [18]
and Censored Least Absolutes Deviations (CLAD) [19].
OLS regression is the most widely used of these estimators
in the literature. It relies on the Gauss Markov assump-
tions about the data and variables used in the model,
which need to be met in order to produce unbiased esti-
mators [20]. Tobit regression was used to account for the
non-trivial proportion of the study population with maxi-
mum EQ-5D VAS scores or EQ-5D utility scores [20,21].
The main assumptions of the Tobit model are that the
error term has a normal distribution and that it has con-
stant variance. If there is heteroskedasticity present, this
may lead to inconsistent estimators being produced. Alter-
natively, when there are specification issues with the Tobit
model, Powell’s Censored Least Absolutes Deviation
(CLAD) estimator can be applied. The CLAD estimator is
a generalisation of the least absolute deviations estimator
[19]. The fractional logit model (Flogit) [18] provides a
further alternative to the OLS and Tobit estimators. The
Flogit model considers the dependent variable as a count,
rather than a continuous variable, by using logit trans-
formation and binomial regression. There is no single
empirical test to evaluate the performance of these alter-
native estimators, so we developed an a priori plan based
on comparable studies. Our aim was to investigate
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curate estimates. Mean absolute errors (MAEs) and root
mean squared errors (RMSEs) were used to examine dif-
ferences between predicted and observed EQ-5D VAS and
utility scores and to also check model performance [22].
All models were tested for heteroskedasticity using the
White test [20]. Once a suitable model had been chosen,
bi-variate analyses were conducted to estimate the un-
adjusted effects of ethnicity on EQ-5D VAS and utility
scores. Partially adjusted and fully adjusted multi-variate
models were then estimated. In the partially adjusted
multivariate models, additional independent variables in-
cluded age (continuous variable), gender (male, female),
marital status (single, married, divorced, widowed) and
the Carstairs deprivation index (categorical variable, see
Table 1 for categories). The Carstairs index is an index of
deprivation, based on four census indicators: low social
class, lack of car ownership, overcrowding and male
unemployment. In the original UKADS data, patient post-
codes were collected, which were linked to the area
specific Carstairs deprivation index, with higher scores
representing elevated deprivation and vice versa [23]. In
the fully adjusted models, further independent variables
included body mass index (BMI) (18.5-24.9, <18.5, 25.0-
29.9, 30.0-34.9, 35.0-39.9, >40.0), smoking status (non-
smoker, current smoker, ex-smoker), alcohol use (yes, no),
duration of diabetes in years (0–1, 2–5, 6–10, 11–15, >15),
treatment regime (diet, tablets, insulin, insulin and tablets),
family history of diabetes (yes, no), history of cardio-
vascular disease (CVD) (yes, no), albumin concentration
(proteinuria and microalbuminuria were defined as urinary
albumin to creatinine ratio (UACR) > =30.0 mg/mmol for
both males and females and UACR 2.5 – <30.0 mg/mmol
for males and 3.5- < 30.0 mg/mmol for females, respec-
tively, with values below these thresholds indicating nor-
mal albuminuria) and GP practice.
Finally to allow for potential clustering effects and con-
founding, the SAS PROC MIXED procedure was sepa-
rately used to fit hierarchical, combined fixed and random
effects models. Random effects were fitted, within a sub-
ject term for general practice, allowing for different in-
tercepts for all individual practices (random intercepts
models).
The bulk of the analyses were conducted using SPSS
19.0, STATA 11 and SAS 9.3. Differences were con-
sidered statistically significant if p-values were less than
0.05.
Results
Table 1 describes the characteristics of each ethnic group.
The south Asian sample was younger than the white
European group, with a mean age of 57 (standard devia-
tion (SD) 11.9) vs. 64.8 (SD 11.6); this difference was sta-
tistically significant (p < 0.001). Duration of diabetes wassignificantly longer (p < 0.001) for the south Asian com-
pared with the white European sample (Table 1). More
south Asians were treated with insulin or a combination
of insulin and tablets, compared with white Europeans
(18.3% vs. 13.2%), while more white Europeans con-
trolled their diabetes solely through diet (28.9% vs.
11.8%). These patterns were also observed in the study
by Bellary et al. [24].
A family history of diabetes was recorded for 50% of pa-
tients, with the proportion significantly higher for south
Asians compared to their white European counterparts.
18% of South Asians had some history of cardiovascular
disease and approximately 28% had some indication of ne-
phropathy (Table 1). However, the presence of chronic
heart disease and microalbuminuria was higher in the
white European sample, whilst proteinuria was more
common amongst south Asians, in comparison to white
Europeans.
Most study participants had BMI scores that were
above normal (88.6%), with a high proportion of the
white European sample classed as obese (54.7%). Using
WHO cut-offs for Asian populations, 14% of south
Asians were overweight (BMI of 23–24.9) and 80% were
obese (BMI of ≥25) [25]. The majority of the sample was
non-smokers; however, more white Europeans than
south Asians were ex-smokers (37.8% vs. 8.6%). Current
alcohol consumption was reported for 182 (12.2%) south
Asians compared to 261 (53.0%) of the white Europeans.
The mean Carstairs index was significantly higher (indi-
cating residence in areas of higher deprivation) for south
Asians at 6.6 (SD 4.6) compared to the white European
sample, whose mean score was 1.7 (SD 3.1) (Table 1). Of
the south Asian subgroups, Pakistani and Bangladeshi
patients were more likely to reside in highly deprived
areas.
Table 2 shows proportions of patients with sub-optimal
levels of function within EQ-5D dimensions by ethnicity.
For all dimensions except mobility a higher proportion of
south Asians experienced sub-optimal function compared
to their white European counterparts. Most notably, over
50% of the south Asian and white European meta-groups
reported sub-optimal function for the pain/discomfort
dimension, although the difference between ethnic meta-
groups was not statistically significant. For the dimensions
of anxiety/depression and usual activities, the proportion
of south Asians reporting sub-optimal levels of func-
tion was significantly higher (p = 0.01 for usual activities,
p = 0.02 for anxiety/depression) compared to their white
European counterparts.
Model diagnostics comparing the different estimators
for the fully adjusted multivariate models are summarised
in online Additional file 1: Table S1 (EQ-5D VAS scores)
and online Additional file 1: Table S2 (EQ-5D utility
scores). The estimator with the smallest MAE and RMSE
Table 1 Characteristics of the study population by ethnicity
Indians Pakistanis Bangladeshis Other South Asians All South Asians White Europeans p-value†
(n = 461) (n = 876) (n = 138) (n = 11) (n = 1486) (n = 492)
Age (years)
Mean [SD] 59.5 [11.4] 56.2 [11.9] 54.3 [11.5] 49.5 [11.5] 57.0 [11.9] 64.8 [11.6] <0.0001
Gender
Male; n (%) 267 (58.0) 438 (50.0) 65 (47.1) 6 (54.6) 776 (52.2) 287 (58.6) 0.015
Female; n (%) 193 (42.0) 438 (50.0) 73 (52.9) 5 (45.5) 709 (47.7) 203 (41.4)
Marital status
Single; n (%) 8 (1.8) 2 (0.2) 0 (0.0) 1 (9.1) 11 (0.7) 38 (8.0) <0.0001
Married; n (%) 402 (90.1) 811 (93.0) 128 (92.8) 9 (81.8) 1350 (90.8) 358 (75.1)
Widowed; n (%) 31 (7.0) 53 (6.1) 9 (6.5) 1 (9.1) 94 (6.3) 49 (10.0)
Divorced; n (%) 5 (1.1) 6 (0.7) 1 (0.7) 0 (−) 12 (0.8) 32 (6.7)
Carstairs index score
Mean [SD] 2.9 [3.6] 8.2 [4.0] 8.2 [4.1] 9.0 [4.6] 6.6 [4.6] 1.7 [3.1] <0.0001
−5 – 0.49, n (%) 133 (29.0) 51 (5.9) 8 (5.8) 0 (0.0) 192 (13.0) 202 (42.1)
0.5 – 3.9, n (%) 159 (34.7) 74 (8.6) 14 (10.2) 2 (18.2) 249 (16.9) 160 (33.3)
4.0 – 6.9, n (%) 97 (21.2) 184 (21.3) 32 (23.4) 2(18.2) 315(21.4) 83 (17.3)
7.0 – 9.9, n (%) 62 (13.5) 257 (29.7) 39 (28.5) 1 (9.1) 359(24.4) 32 (6.7)
10.0 – 17.0, n (%) 7 (1.5) 300 (34.6) 44 (32.1) 6(54.6) 357(24.3) 3 (0.6)
Smoking status
Non-smoker; n (%) 407 (88.3) 634 (72.4) 89 (64.5) 5 (45.5) 1135 (76.4) 231 (47.0) <0.0001
Current smoker; n (%) 29 (6.3) 156 (17.8) 36 (26.1) 2 (18.2) 223 (15.0) 75 (15.2)
Ex-smoker; n (%) 25 (5.4) 86 (9.8) 13 (9.4) 4 (36.4) 128 (8.6) 186 (37.8)
Alcohol use
No; n (%) 298 (64.6) 858 (97.9) 138 (100) 10 (90.9) 1304 (87.8) 231 (47.0) <0.0001
Yes; n (%) 163 (35.4) 18 (2.1) 0 (−) 1 (9.1) 182 (12.2) 261 (53.0)
BMI score
Mean [SD] 28.3 [5.0] 28.9 [5.3] 26.5 [4.0] 29.6 [5.6] 28.5 [5.1] 30.9 [7.3] <0.0001
< 18.5; n (%) 1 (0.2) 2 (0.2) 0 (−) 0 (−) 3 (0.2) 5 (1.0)
18.5 – 24.9; n (%) 88 (19.1) 156 (17.8) 46 (33.3) 2 (18.2) 292 (19.7) 74 (15.0)
25.0 – 29.9; n (%) 218 (47.3) 370 (42.2) 64 (46.4) 4 (36.4) 656 (44.2) 144 (29.3)
30.0 – 34.9; n (%) 106 (23.0) 231 (26.4) 20 (14.5) 3 (27.3) 360 (24.2) 156 (31.7)
35.0 – 39.9; n (%) 36 (7.8) 86 (9.8) 7 (5.1) 2 (18.2) 131 (8.8) 57 (11.6)
>40.0; n (%) 12 (2.6) 31 (3.5) 1 (0.7) 0 (0.0) 44 (3.0) 56 (11.4)
Duration of diabetes (years)
Mean [SD] 7.6 [7.0] 7.7 [6.7] 8.5 [6.1] 3.9[4.6] 7.7 [6.7] 6.3 [7.0] <0.0001
0 – 1years, n (%) 80 (17.4) 126 (14.4) 7 (5.1) 2 (18.2) 215 (14.5) 74 (15.0)
2 – 5years, n (%) 154 (33.4) 304 (34.7) 51 (37.0) 8 (72.7) 517 (34.8) 226 (45.9)
6 – 10years, n (%) 113 (24.5) 215 (24.5) 31 (22.5) 0 (−) 359 (24.2) 111 (22.6)
11 – 15years, n (%) 50 (10.9) 116 (13.2) 29 (21.0) 0 (−) 195 (13.1) 41 (8.3)
>15years, n (%) 64 (13.9) 115 (13.1) 20 (14.5) 1 (9.1) 200 (13.5) 40 (8.1)
Diabetes treatment
Diet only; n (%) 48 (10.4) 113 (12.9) 13 (9.4) 2 (18.2) 176 (11.8) 142 (28.9) <0.0001
Tablets; n (%) 328 (71.2) 587 (67.0) 97 (70.3) 8 (72.7) 1038 (69.9) 285 (57.9)
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Table 1 Characteristics of the study population by ethnicity (Continued)
Insulin; n (%) 47 (10.2) 73 (8.3) 12 (8.7) 1 (9.1) 128 (8.6) 35 (7.1)
Tablets and Insulin; n (%) 38 (8.2) 103 (11.8) 16 (11.6) 0 (−) 144 (9.7) 30 (6.1)
Family history of diabetes
No; n (%) 236 (51.2) 386 (44.1) 75 (54.3) 3 (27.3) 700 (47.1) 287 (58.3) <0.0001
Yes; n (%) 225 (48.8) 490 (55.9) 63 (45.7) 8 (72.7) 786 (52.9) 205 (41.7)
History of cardiovascular disease
No; n (%) 371 (80.5) 724 (82.7) 114 (82.6) 9 (81.8) 1218 (82.0) 387 (78.7) 0.104
Yes; n (%) 90 (19.5) 152 (17.4) 24 (17.4) 2 (18.2) 268 (18.0) 105 (21.3)
Albumin concentration
Normal; n (%) 303 (72.8) 612 (73.6) 85 (64.4) 7 (77.8) 1007 (72.5) 343 (74.1) <0.0001
Microalbuminuria; n (%) 84 (20.2) 162 (19.5) 33 (25.0) 2 (22.2) 281 (20.2) 109 (23.5)
Proteinuria; n (%) 29 (7.0) 58 (7.0) 14 (10.6) 0 (−) 101 (7.3) 11 (2.4)
EQ-5D utility score
Mean [SD] 0.8 [0.3] 0.6 [0.4] 0.7 [0.3] 0.6 [0.4] 0.7 [0.3] 0.7 [0.3] 0.0005
EQ-5D VAS score
Mean [SD] 63.7 [19.7] 63.2 [22.3] 64.0 [21.4] 69.2 [28.2] 63.5 [21.49] 71.3 [18.1] <0.0001
Missing data: Age 3, gender 3, marital status 34, Carstairs Index 26, proteinuria 126, EQ-5D utility score 272, EQ-5D VAS score 306.
† Comparisons between all south Asians and white Europeans using Student t-tests for continuous variables and χ2 test for categorical variables.
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mator had the largest MAE and RMSE values. The results
for the remaining estimators were broadly comparable
across model type. The White test rejected the hypothesis
of homoscedasticity in the error term (p < 0.01) for all esti-
mators; robust standard errors (SEs) were used to correct
for this. For ease of interpretation, we report the results
for the OLS estimator in our main tables with compara-
tive results across estimators found in online Additional
file 1: Table S3 and S4.
Tables 3 and 4 respectively present results for the OLS
unadjusted, partially adjusted and fully adjusted models
for the EQ-5D VAS and EQ-5D utility scores. For EQ-5D
VAS scores, the impact of being of south Asian descent
was a decrement of 7.82 compared to the white European
counterparts (SE 1.06; p < 0.01) (Table 3). For EQ-5D uti-
lity scores, south Asian descent was, on average, asso-
ciated with a decrement in utility score of 0.06 (SE 0.02,Table 2 Number (%) of patients with sub-optimal levels of fu
Dimension Indians Pakistanis Bangladeshis Ot
(n = 461) (n = 876) (n = 138)
Mobility; n (%) 78 (20.9) 373 (48.3) 45 (36.9)
Self care; n (%) 44 (11.7) 165 (21.4) 25 (20.5)
Usual activities; n (%) 80 (21.3) 322 (41.9) 42 (34.4)
Pain/Discomfort; n (%) 175 (46.9) 529 (68.7) 80 (65.6)
Anxiety/Depression; n (%) 86 (22.9) 290 (37.7) 35 (28.7)
Missing values: Mobility 266, Self care 265, usual activities 269, Pain/Discomfort 269
§Sub-optimal levels of function defined as levels 2 or 3 for each EQ-5D dimension.
†Calculated using Fisher’s exact test for equality of proportions comparing south Asp < 0.01) (Table 4). After controlling for socio-economic
and socio-demographic variables, a significant inverse
association remained between south Asian ethnicity and
EQ-5D VAS scores [−7.30 (SE 1.36, p < 0.01)]. In contrast,
a non-significant association was found between south
Asian ethnicity and EQ-5D utility scores. The fully ad-
justed analyses strengthened the effect of south Asian eth-
nicity on EQ-5D VAS scores [−9.35 (SE 2.46, p <0.01)]
(Table 3), whilst the effect on EQ-5D utility scores
remained insignificant [0.06 (SE 0.04)] (Table 4). Results of
the separate mixed effects models, which included random
intercepts for individual general practices, were very similar
to the final OLS estimates; for EQ-5D VAS scores −9.31,
p = 0.0002 and for EQ-5D utility scores −0.02, p = 0.5751.
Unadjusted, partially adjusted and fully adjusted ana-
lyses were also conducted for south Asian subgroups and
can be found in online Additional file 1: Table S5 and S6.
In the fully adjusted model, all south Asian ethnicitiesnction§ within each EQ-5D dimension
her South Asians All South Asians White Europeans p-value†
(n = 11) (n = 1486) (n = 492)
4 (40.0) 500 (39.1) 198 (45.6) 0.017
3 (30.0) 237 (18.5) 64 (14.8) 0.074
4 (40.0) 448 (35.1) 123 (28.3) 0.010
7 (70.0) 791 (62.0) 250 (57.6) 0.102
4 (40.0) 415 (32.5) 115 (26.5) 0.020
, Anxiety/Depression 277.
ians and white European.
Table 3 Ordinary least squares estimator of marginal effects for EQ-5D VAS scores
Unadjusted β
[Robust SE] (n = 1706)
Partially adjusted β
[Robust SE] (n = 1654)
Fully adjusted β
[Robust SE] (n = 1545)
Ethnicity (Referent =White Europeans)
All South Asians -0.06 [0.02]** 0.02 [0.02] 0.06 [0.04]
Age (years) -0.002 [0.001]* -0.002 [0.001]**
Gender (Referent = Male)
Female -0.10 [0.02]** -0.10 [0.02]**
Marital status (Referent = Single)
Married -0.08 [0.03]** -0.07 [0.03]*
Widowed -0.03 [0.04] -0.02 [0.04]
Divorced -0.14 [0.07]* -0.18 [0.06]**
Ethnicity (Referent =White Europeans)
Carstairs index (Referent = 10.0-17.0)
-5 – 0.49 0.20 [0.03]** 0.05 [0.03]
0.5 – 3.9 0.16 [0.03]** 0.02 [0.03]
4.0 – 6.9 0.10 [0.03]** 0.01 [0.03]
7.0 – 9.9 0.08 [0.03]** 0.04 [0.03]
Smoking status (Referent = Non Smoker)
Current smoker -0.02 [0.02]
Ex-smoker -0.05 [0.02]*
Alcohol use (Referent = No)
Yes 0.003 [0.02]
BMI score (Referent 18.5 – 24.9)
< 18.5 -0.19 [0.13]
25.0 – 29.9 -0.02 [0.02]
30.0 – 34.9 -0.08 [0.02]**
35.0 – 39.9 -0.14 [0.03]**
>40.0 -0.18 [0.04]**
Duration of diabetes (Referent = 0-1 years)
2 – 5 years -0.04 [0.02]
6 – 10 years -0.04 [0.03]
11 – 15 years -0.06 [0.03]
>15 years -0.04 [0.03]
Tablets -0.004 [0.02]
Insulin -0.08 [0.04]*
Tablets and Insulin -0.05 [0.03]
Family history of diabetes (Referent = No)
Yes 0.01 [0.02]
History of chronic heart disease (Referent = No)
Yes -0.07 [0.02]**
Albumin concentration (Referent = Normal)
Microalbuminuria 0.03 [0.02]
Proteinuria -0.03 [0.04]
Constant 0.73 [0.01]** 0.79 [0.05]** 0.89 [0.08]**
*p-value <0.05; **p-value <0.01.
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Table 4 Ordinary least squares estimator of marginal effects for EQ-5D utility scores
Unadjusted β
[Robust SE] (n = 1706)
Partially adjusted β
[Robust SE] (n = 1654)
Fully adjusted β
[Robust SE] (n = 1545)
Ethnicity (Referent =White Europeans)
All South Asians -0.06 [0.02]** 0.02 [0.02] 0.06 [0.04]
Age (years) -0.002 [0.001]* -0.002 [0.001]**
Gender (Referent = Male)
Female -0.10 [0.02]** -0.10 [0.02]**
Marital status (Referent = Single)
Married -0.08 [0.03]** -0.07 [0.03]*
Widowed -0.03 [0.04] -0.02 [0.04]
Divorced -0.14 [0.07]* -0.18 [0.06]**
Carstairs index (Referent = 10.0-17.0)
-5 – 0.49 0.20 [0.03]** 0.05 [0.03]
0.5 – 3.9 0.16 [0.03]** 0.02 [0.03]
4.0 – 6.9 0.10 [0.03]** 0.01 [0.03]
7.0 – 9.9 0.08 [0.03]** 0.04 [0.03]
Smoking status (Referent = Non Smoker)
Current smoker -0.02 [0.02]
Ex-smoker -0.05 [0.02]*
Alcohol use (Referent = No)
Yes 0.003 [0.02]
BMI score (Referent 18.5 – 24.9)
< 18.5 -0.19 [0.13]
25.0 – 29.9 -0.02 [0.02]
30.0 – 34.9 -0.08 [0.02]**
35.0 – 39.9 -0.14 [0.03]**
>40.0 -0.18 [0.04]**
Duration of diabetes (Referent = 0-1 years)
2 – 5 years -0.04 [0.02]
6 – 10 years -0.04 [0.03]
11 – 15 years -0.06 [0.03]
>15 years -0.04 [0.03]
Diabetes treatment (Referent = Diet only)
Tablets -0.004 [0.02]
Insulin -0.08 [0.04]*
Tablets and Insulin -0.05 [0.03]
Family history of diabetes (Referent = No)
Yes 0.01 [0.02]
History of chronic heart disease (Referent = No)
Yes -0.07 [0.02]**
Albumin concentration (Referent = Normal)
Microalbuminuria 0.03 [0.02]
Proteinuria -0.03 [0.04]
Constant 0.73 [0.01]** 0.79 [0.05]** 0.89 [0.08]**
*p-value <0.05; **p-value <0.01.
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scores compared to the white European ethnic origin (on-
line Additional file 1: Table S5); the most significant decre-
ment was observed for patients of Indian origin. In
contrast, when the EQ-5D utility scores were analysed by
ethnic sub-group, the fully adjusted model revealed no sig-
nificant decrements in scores for each of the south Asian
ethnicities compared to those of white European ethnic
origin (online Additional file 1: Table S6).
Discussion
In this study, the baseline disease profile of the south
Asian patients mirrored that reported in the broader
literature; younger people with a longer disease duration,
increased severity of disease (as measured by type of
treatment), and a higher incidence of family history of
the disease, compared to the white European population.
However, indications of CVD and albumin concentration
were slightly lower in the south Asian group. This may
be attributable to the population being younger and also
to lifestyle factors, as south Asian patients did not
smoke as much and consumed less alcohol than the
white European sample. However, the percentage of
current smokers in the sample (15%) was less than the
current smoking population in England (21%) [26]. Simi-
larly, the percentage of people who consumed alcohol in
the entire sample (22%) was less than the comparative
figure for England (63%) [27]. The south Asian popula-
tion resided in areas with higher levels of deprivation
than the white European sample. Mean EQ-5D VAS and
utility scores were lower than for white European pa-
tients; with more of the south Asian population repor-
ting sub-optimal levels of function across the self care,
usual activities, and pain and anxiety/depression dimen-
sions of the EQ-5 D. Mobility was the one dimension for
which the White European sample reported higher sub-
optimal levels of function. This could be related to the
fact that the White European sample had a mean age of
64 years compared to a mean age of 57 years for the
south Asians.
Our regression analyses indicate that south Asian ethni-
city has an overall negative impact on EQ-5D VAS scores
in patients with type 2 diabetes. On average, EQ-5D VAS
scores were 9.35 lower for south Asians compared to
white European patients in the fully adjusted OLS model.
Comparison of the ethnic subgroups showed that Indians
experienced the largest negative decrement in EQ-5D
VAS scores compared to their white European counter-
parts in the adjusted analyses. Lower EQ-5D utility scores
in south Asians were also observed, with south Asians
experiencing an adjusted utility decrement of 0.06 com-
pared to the white European sample. However, the effects
on EQ-5D utility scores were only significant in the un-
adjusted analyses. It should be noted that a difference of0.05 in mean multi-attribute utility scores is deemed cli-
nically important for evaluative purposes [28]. The results
of the regression analyses for both the EQ-5D VAS
and utility scores remained robust to alternative model
estimators.
The study revealed a consistent negative association bet-
ween south Asian ethnicity and the EQ-5D VAS scores in
patients with type 2 diabetes. In the broader literature, there
are few studies that used the EQ-5D measure to assess
HRQoL in ethnic minority populations with diabetes. Of
the studies that did use this measure, Lubetkin et al. [14]
reported results similar to the present study. The authors
had used the EQ-5D measure to compare HRQoL between
African-Americans, Hispanics and white Americans and
found that after adjusting for known determinants of
HRQoL, including chronic conditions such as diabetes;
Hispanics had lower EQ-5D VAS scores and slightly higher
EQ-5D utility scores compared to the white American
sample. However, African Americans experienced both
higher EQ-5D VAS and utility scores compared to the
white American population. Although these results are
similar in some respects to the ones reported here, they
may not be generalisable due to the fact that different
ethnic minority populations were studied. Differences may
also be attributable to other methodological factors; for
example, Lubetkin et al. [14] controlled for income, edu-
cation and six chronic conditions in their study. In the
current study, no data were available for income or edu-
cation although lifestyle factors, co-morbidities and area
deprivation were all included. In addition, cultural diffe-
rences in rating tendencies have been observed in some
studies. Lubetkin et al. [14] discussed the possibility that
US Asians may be averse to valuing their health at the
upper end of the VAS scale and may choose values towards
the middle of the scale. This could partly account for any
consistently negative association between ethnic minority
status and EQ-5D VAS scores. In contrast, for EQ-5D util-
ity scores, although individuals’ describe their own health-
related quality of life, the values placed on those descrip-
tions reflect general population preferences for health
states. Moreover, a different valuation technique (the time
trade-off approach) is used to derive those values. In
the present study, there were patients who reported low
EQ-5D VAS scores, such as a score of 20, but who had
EQ-5D utility scores at the upper end of the utility scale,
for example 0.8. Clearly, further research is required that
disentangles the effects of the valuation technique itself
and the underpinning source of values when assessing
ethnicity-related effects on the HRQoL of individuals with
type 2 diabetes.
One caveat to this study was the absence of information
on education levels in the two samples. A lower level of
education has been shown to be associated with impaired
HRQoL [14]. Furthermore, as diabetes is a self-managed
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self-management and control of the disease, which in its
turn should promote HRQoL. A study by Thoolen et al.
examined the characteristics of patients with diabetes who
participate in diabetes self-management programmes [29].
The authors found that education level was the most
important factor differentiating participants and non-
participants/dropouts, with participation linked to higher
education levels. Since the south Asian sample in our
study, on average, resided in areas with higher levels of
deprivation compared to the White European sample, it is
possible that their educational levels were also lower than
in the white Europeans. By not adjusting for this dif-
ference between the two groups in the regressions, edu-
cation effects may be reflected in the error terms of our
models. A second caveat to the study revolves around the
estimators selected to model the association between
ethnicity and EQ-5D VAS or utility scores. Our selection
of OLS, Tobit, Flogit and CLAD estimators was in keeping
with the modelling approaches used more broadly by
health economists to estimate EQ-5D values [16,30]. Fur-
thermore, our statistical plan for model selection, which
included the use of MAEs, RMSEs and tests for heteroske-
dasticity was in keeping with recommended diagnostic ap-
proaches [22]. Nevertheless, a number of methodological
concerns surround the application of these estimators
when modelling EQ-5D data. The OLS estimator does not
capture the ceiling effect at 1.0 for utility values, whilst the
Tobit and CLAD estimators may generate biased results
when the true utility is conceptually bounded above at 1.0
[31,32]. The FLogit estimator has not previously been
used on an extensive basis in the modelling utility data
literature; a recent application did not generate promising
results [33]. Alternative estimators for modelling health
state utility values, such as adjusted limited dependent
variable mixture models, are currently under development
[34]; their application to UKADS data remains a topic for
future enquiry.Conclusion
The study suggests that south Asian ethnicity has a
negative effect on both the EQ-5D VAS and utility
scores compared to white Europeans. However no sta-
tistically significant difference was observed for utility
scores when socio-economic, demographic and clinical
variables were included in the models. Moreover, as
observed in the broader literature, the nature and mag-
nitude of the HRQoL effects vary depending on the
ethnic minority under consideration [12,14]. Further re-
search is needed to explain the differences in ethnicity-
related effects on subjective EQ-5D VAS scores and
population-weighted EQ-5D utility scores in patients
with type 2 diabetes.Additional file
Additional file 1: Table S1. Estimated predicted scores compared to
observed EQ-5D VAS scores (fully adjusted model for all south Asians).
Table S2. Estimated predicted scores compared to observe EQ-5D utility
scores (fully adjusted model for all south Asians). Table S3. Marginal
effects for EQ-5D VAS scores for all south Asians† by estimator and model.
Table S4. Marginal effects for EQ-5D utility scores for all south Asians† by
estimator and model. Table S5. OLS marginal effects of sub-group south
Asian ethnicity on EQ-5D VAS scores†±. Table S6. OLS marginal effects of
sub-group south Asian ethnicity on EQ-5D utility scores†±.
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